New antibody drug shows promise in early lung cancer trial

NCT ID NCT02609776

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage trial tests a new drug called amivantamab in people with advanced non-small cell lung cancer. The drug is a special antibody that targets two proteins on cancer cells. Researchers are checking safety and how well it works, both alone and with other treatments. About 751 participants are enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Amivantamab (a bispecific antibody targeting EGFR and cMet), given alone or with lazertinib or chemotherapy
What this could lead to: If successful, this could provide a new treatment option for people with advanced non-small cell lung cancer who have not responded to other therapies.
What could go wrong: This is an early phase 1 trial, so the drug may not prove effective or may cause serious side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Study site

Duarte, California, United States
Study site

La Jolla, California, United States
Study site

Orange, California, United States
Study site

Santa Monica, California, United States
Study site

West Hollywood, California, United States
Study site

Tampa, Florida, United States
Study site

Chicago, Illinois, United States
Study site

Bethesda, Maryland, United States
Study site

Boston, Massachusetts, United States
Study site

Detroit, Michigan, United States
Study site

Rochester, Minnesota, United States
Study site

St Louis, Missouri, United States
Study site

New York, New York, United States
Study site

Portland, Oregon, United States
Study site

Philadelphia, Pennsylvania, United States
Study site

Houston, Texas, United States
Study site

Fairfax, Virginia, United States
Study site

Camperdown, Australia
Study site

Heidelberg, Australia
Study site

Kogarah, Australia
Study site

Murdoch, Australia
Study site

Woolloongabba, Australia
Study site

Toronto, Ontario, Canada
Study site

Beijing, China
Study site

Changchun, China
Study site

Changsha, China
Study site

Chengdu, China
Study site

Chongqing, China
Study site

Guangzhou, China
Study site

Hangzhou, China
Study site

Hefei, China
Study site

Nanchang, China
Study site

Nanjing, China
Study site

Wuhan, China
Study site

Zhengzhou, China
Study site

Bordeaux, France
Study site

Dijon, France
Study site

Lyon, France
Study site

Marseille, France
Study site

Paris, France
Study site

Saint-Herblain, France
Study site

Villejuif, France
Study site

Chūōku, Japan
Study site

Hyōgo, Japan
Study site

Kashiwa, Japan
Study site

Kurume, Japan
Study site

Nagoya, Japan
Study site

Niigata, Japan
Study site

Osaka, Japan
Study site

Tokyo, Japan
Study site

Wakayama, Japan
Study site

Yonago, Japan
Study site

Cheongju-si, South Korea
Study site

Goyang-si, South Korea
Study site

Incheon, South Korea
Study site

Seongnam-si, South Korea
Study site

Seoul, South Korea
Study site

A Coruña, Spain
Study site

Barcelona, Spain
Study site

Madrid, Spain
Study site

Málaga, Spain
Study site

Santander, Spain
Study site

Seville, Spain
Study site

Kaohsiung City, Taiwan
Study site

Taichung, Taiwan
Study site

Taipei, Taiwan
Study site

Manchester, United Kingdom
Study site

Newcastle upon Tyne, United Kingdom
Study site

Sutton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.